Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 13/20 | 0.82 |
| ▸ | HDAC4 | P56524 | 13/20 | 0.82 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.82 |
| ▸ | HDAC7 | Q8WUI4 | 13/20 | 0.82 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.82 |
| ▸ | HDAC10 | Q969S8 | 13/20 | 0.82 |
| ▸ | HDAC11 | Q96DB2 | 13/20 | 0.82 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.82 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.82 |
| ▸ | HDAC9 | Q9UKV0 | 13/20 | 0.82 |
| ▸ | HDAC5 | Q9UQL6 | 13/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | GLA | P06280 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.50 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19207462 | 0.93 | HDAC3 (0.75) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19254250 | 0.93 | HDAC3 (0.75) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19207425 | 0.92 | HDAC3 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19254248 | 0.92 | HDAC3 (0.79) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19254091 | 0.92 | HDAC3 (0.73) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19207430 | 0.91 | HDAC3 (0.73) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19254655 | 0.91 | HDAC3 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19254335 | 0.91 | HDAC3 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19207440 | 0.91 | HDAC3 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19254661 | 0.91 | HDAC3 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10765681-B2 | Purine compounds possessing anticancer activity | ACADEMIA SINICA (TW) | 2020-09-08 | — | — | US | disclosed |
| US-10765681-B2 | Purine compounds possessing anticancer activity | ACADEMIA SINICA (TW) | 2020-09-08 | — | — | US | disclosed |
| US-20180369249-A1 | PURINE COMPOUNDS POSSESSING ANTICANCER ACTIVITY | ACADEMIA SINICA (TW) | 2018-12-27 | — | — | US | disclosed |
| WO-2017136689-A1 | PURINE COMPOUNDS POSSESSING ANTICANCER ACTIVITY | ACADEMIA SINICA (TW) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017136689-A1 | PURINE COMPOUNDS POSSESSING ANTICANCER ACTIVITY | ACADEMIA SINICA (TW) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369249-A1 | PURINE COMPOUNDS POSSESSING ANTICANCER ACTIVITY | NTPCR, PNP, NUDT1 | HDAC3 4153/4885HDAC4 3608/4885HDAC1 2598/4885 |
| US-10765681-B2 | Purine compounds possessing anticancer activity | NTPCR, PNP, NUDT1 | HDAC3 4153/4885HDAC4 3608/4885HDAC1 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.